Dailypharm Live Search Close

Kadcyla to recieve reimb in early breast cancer from July

By Lee, Tak-Sun | translator Alice Kang

22.06.22 06:18:11

°¡³ª´Ù¶ó 0
HIRA conducts opinion inquiry on the revision of the reimbursement standards¡¦ sold ₩52.7 billion only in last year



Roche Korea¡¯s Kadcyla inj. (ado-trastuzumab emtansine) is expected to additionally receive insurance benefits for early breast cancer in Korea.

Kadcyla, a breast cancer treatment that Roche released to succeed Herceptin, has been limitedly used in patients with locally advanced or metastatic breast cancer in Korea until now.

The Health Insurance Review and Assessment Service announced that it will conduct an opinion inquiry on the revision of the ¡®notice on pharmaceuticals prescribed and administered to cancer patients¡¯ that contains the reimbursement standards for Kadcyla in early breast cancer until the 27th. Its expected implementation date is July 1st.

The revision

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)